Our Story

A New Class of Company

Revalia Bio was founded at the intersection of transplant science, data infrastructure, and drug development to solve one of medicine's most pressing failures.

Revalia Bio emerged from Yale's transplant research community, where co-founders Greg Tietjen and Jenna DiRito recognized that the infrastructure for ex vivo organ research — the ability to keep donated organs viable for research outside the body — could be transformed into a systematic platform for human drug testing.

Today, Revalia operates a 8,000 sq ft facility in New Haven, CT and maintains partnerships with transplant centers across the country. With a $26.7M ARPA-H contract and backing from leading life sciences investors, we are building the infrastructure that will transform how drugs are developed for generations to come.

Backed By